For the many patients who do not achieve guideline-driven LDL-C targets with statin monotherapy, guidelines recommend either increasing the statin dose or initiating statin therapy in combination with another lipid-lowering agent. In particular, the new American College of Cardiology/American Heart Association guidelines (3) recommend that the maximum tolerated statin dose be used in high-risk individuals, and that the addition of a nonstatin cholesterol-lowering drug may be considered if the risk-reduction benefit outweighs the safety risk in patients with a less than adequate therapeutic response to statins.
The beneficial effects of intensive statin treatment are attributed to the slowing of atherosclerotic plaque progression, and more importantly, to plaque stabilization, as suggested by large IVUS studies of more versus less intensive statin therapy (4, 5) . From the Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose. In particular, it would be interesting to establish the clinical relevance of the potential pleiotropic effects of ezetemibe that operate beyond cholesterol lowering.
The reality is always more complex than we tend to believe, in line with the wise words of Isaac Newton:
"What we know is a drop, what we ignore is an ocean."
